Second, recent studies have not been able to demonstrate the clinical utility of PI3K mutations and other genomic aberrations within the AKT signaling pathway as markers of endocrine response in ER+ breast cancer [26-28,51]. This evidence concerns the gene PIK3CG and breast cancer.